In conclusion, serum and urine IP-10, sGalectin-9, and uSIGLEC-1 seem to be promising biomarkers reflecting global disease activity in patients with SLE although they do not outperform serum C3 and C4. This evidence concerns the gene CXCL10 and systemic lupus erythematosus.